- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| GLUCOTRACK Aktie jetzt für 0€ handeln | |||||
| 16.04. | Glucotrack, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.04. | Glucotrack to bring implantable CBGM to automated insulin delivery system initiative in Europe | 1 | MassDevice | ||
| 03.04. | Glucotrack, Inc.: Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose Monitor | 1 | GlobeNewswire (USA) | ||
| 31.03. | Glucotrack, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 31.03. | GlucoTrack, Inc.: Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights | 59 | GlobeNewswire (Europe) | Transformational 2024: successfully advanced from preclinical to clinical stage company Strengthened leadership team to drive growth and advance clinical development Investigational Device Exemption... ► Artikel lesen | |
| 31.03. | Glucotrack, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.03. | GCTK-Aktie stürzt | 3 | Investing.com Deutsch | ||
| 13.03. | Glucotrack, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.02. | Glucotrack, Inc.: Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member | 1 | GlobeNewswire (USA) | ||
| 26.02. | Glucotrack, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.02. | Glucotrack's 3-year diabetes sensor implant clears initial human safety trial | 1 | FierceBiotech | ||
| 05.02. | Glucotrack, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.02. | GlucoTrack Drops 24% Despite Successful First-in-Human Study Of CGM | - | RTTNews | ||
| 04.02. | Glucotrack announces pricing of $3M public offering | 2 | Seeking Alpha | ||
| 04.02. | Glucotrack sets terms for $3 million public stock offering | 1 | Investing.com | ||
| 04.02. | Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering | 4 | GlobeNewswire (USA) | ||
| 04.02. | Glucotrack soars on completion of first human clinical study of continuous blood glucose monitor | 2 | Seeking Alpha | ||
| 04.02. | Glucotrack completes first-in-human continuous blood glucose monitor implant study | 3 | MassDevice | ||
| 04.02. | Glucotrack reports success in first human glucose monitor trial | 5 | Investing.com | ||
| 04.02. | Glucotrack, Inc.: Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor | 215 | GlobeNewswire (Europe) | RUTHERFORD, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 58,80 | +4,81 % | EQS-News: Eckert & Ziegler SE: Eckert & Ziegler unterzeichnet Herstellungsvereinbarung mit Pentixapharm für Yttrium-90-basiertes PentixaTher | EQS-News: Eckert & Ziegler SE
/ Schlagwort(e): Vereinbarung/Auftragseingänge
Eckert & Ziegler unterzeichnet Herstellungsvereinbarung mit Pentixapharm für Yttrium-90-basiertes... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,127 | -3,79 % | Sernova Aktie: Positives Umsatzwachstum gemeldet! | Das Biotechnologieunternehmen erweitert sein Führungsteam, sichert Finanzierungen und erhält FDA-Freigabe für klinische Studien zur Behandlung von Hypothyreose. Sernova Biotherapeutics, ehemals Sernova... ► Artikel lesen | |
| SYNLAB | 12,840 | +0,47 % | Fitch ändert Synlabs Ausblick auf stabil, bestätigt 'B' IDR | ||
| NUGEN MEDICAL DEVICES | 0,057 | +5,56 % | Osterlektüre: Die 13.000%-Chance für ihr Depot! | ||
| ATOSSA THERAPEUTICS | 0,642 | -0,47 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio | SEATTLE, April 22, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast... ► Artikel lesen | |
| PING AN HEALTHCARE | 0,804 | 0,00 % | Ping An Healthcare and Technology Company Limited: Ping An Health Reports 25.8% Year-on-Year Revenue Growth in Q1 2025, with Profitability Accelerating | Revenue and Profit Surge, Driven by "AI + Health Care" Value Empowerment
SHANGHAI and HONG KONG, April 24, 2025 /PRNewswire/ -- Ping An Healthcare and Technology... ► Artikel lesen | |
| UNIDOC HEALTH | 0,185 | -9,73 % | UniDoc Health Corp.: UniDoc Announces LIFE Offering | THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / April 4, 2025 / UniDoc Health Corp. (CSE:UDOC) ("UniDoc"... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 | - Improved loss from operations by 31% -
- Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,065 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy Chain | BOULDER, CO / ACCESS Newswire / April 22, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen | |
| MOUNTAIN VALLEY MD | 0,013 | 0,00 % | Mountain Valley MD Holdings Inc: Mountain Valley hopes for continued growth in 2025 | ||
| CO-DIAGNOSTICS | 0,320 | +1,91 % | Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results | SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the... ► Artikel lesen | |
| CYTOSORBENTS | 1,060 | +4,54 % | CytoSorbents Gains $1.7M Via NJEDA Tax Credit Sale To Fund Strategic Growth | ||
| VERU | 0,468 | -3,70 % | Veru Aktie: Bedeutet das eine Neuausrichtung? | Die Veru-Aktie verliert weiter an Wert, doch Analysten bleiben optimistisch aufgrund vielversprechender Medikamentenentwicklungen. Wird der Tiefpunkt bald erreicht? Die Veru-Aktie setzt ihre Abwärtsspirale... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 7,050 | -100,00 % | Tempest Therapeutics: Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP | BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics... ► Artikel lesen | |
| QUIDELORTHO | 25,000 | +2,46 % | QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Results | SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care... ► Artikel lesen |
GLUCOTRACK INC gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von -0,001 (-0,56 %) liegt der Kurs bei 0,160 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GLUCOTRACK INC finden Sie auf Wallstreet Online.
